About
Cancer Therapy
Areas of Focus
Categories
Small Molecule PharmaceuticalSan Diego & Southern California
Team (2)
Clinical Trials (12)
View allTotal Trials
12
As Lead Sponsor
7
As Collaborator
5
Total Enrollment
673
By Phase
PHASE1/PHASE2: 4PHASE2: 5EARLY_PHASE1: 1
By Status
COMPLETED: 6RECRUITING: 3ACTIVE_NOT_RECRUITING: 2NO_LONGER_AVAILABLE: 1
Clinical Trials Pipeline11 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
Today
Hover over trial bars to see details
Recent Trials
NCT06736717Collaborator
Onvansertib in Combination With NALIRIFOX for First Line Treatment of Advanced Pancreatic Cancer
PHASE1/PHASE2Recruiting
21 participants
Started: Feb 28, 2025 · Completed: Jan 31, 2027
NCT06106308Lead Sponsor
Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation
PHASE2Active, not recruiting
113 participants
Started: Feb 27, 2024 · Completed: Jan 31, 2027
NCT05593328Lead Sponsor
Study of Onvansertib in Combination With FOLFIRI and Bevacizumab Versus FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer in Participants With a Kirsten Rat Sarcoma Virus Gene (KRAS) or Neuroblastoma-RAS (NRAS) Mutation
PHASE2Completed
23 participants
Started: Mar 17, 2023 · Completed: Dec 9, 2024
NCT05383196Collaborator
Onvansertib + Paclitaxel In TNBC
PHASE1/PHASE2Active, not recruiting
50 participants
Started: Sep 30, 2022 · Completed: Feb 15, 2029
NCT05450965Collaborator
Study of PLK1 Inhibitor, Onvansertib, in Relapsed Small Cell Lung Cancer
PHASE2Recruiting
37 participants
Started: Jul 19, 2022 · Completed: Nov 30, 2027
Locations (1)
Headquarters
San Diego, CA, United States
Map
Loading map...